Maternal Pertussis Vaccine Coverage Falls to a Six-Year Low in England
England’s pertussis vaccination programme for pregnant women lost ground again in spring 2022, with coverage sliding to its lowest level since the current IT specification began in April 2016. For women who delivered between April and June 2022, monthly coverage measured 61.5% in April, 60.4% in May, and 59.5% in June, leaving the quarter at a mean of 60.6%.
The decline is not subtle. Compared with the same quarter in 2021 to 2022, mean coverage was 3.9 percentage points lower, and it was 8.9 percentage points lower than the same quarter in 2020 to 2021. In practical terms, fewer pregnant women were receiving protection during the window when transplacental antibody transfer can help shield newborns from infection before they are old enough for their own primary immunisation series.
London’s Drop Set the Tone for the National Trend
The sharpest regional deterioration came in London, where coverage has fallen steadily since December 2019. By June 2022, London’s NHS commissioning region had dropped to 37.6%, down 23.3 percentage points from 60.9% in December 2019. The report also states that this observed decline has largely been driven by London, where coverage in June 2022 was 15.2 percentage points lower than in June 2020.
A single sentence captures the policy problem: London now sits far below the national mean and has become the dominant drag on England’s overall coverage.
The local spread within the country was wide enough to matter clinically and operationally. Across sustainability and transformation plan areas during the quarter, coverage ranged from 20.6% in North London Partners in Health and Care in June 2022 to 78.0% in Humber, Coast and Vale in April 2022. Even within the same quarter, the difference between the highest and lowest STP monthly coverage reached 46.9 percentage points, a reminder that the maternal programme is only as strong as its weakest local delivery system.
Routine Antenatal Protection Depends on Accurate Record Capture
The programme’s measurement system is built on general practice data automatically uploaded to the ImmForm website by participating GP IT suppliers. The denominator includes women who delivered in the survey month, excluding miscarriages and stillbirths, and the numerator counts those who received a pertussis-containing vaccine between week 16 of pregnancy and delivery. That structure depends on reliable clinical record entry, especially the date of delivery, the date of vaccination, and fields identifying stillbirth or miscarriage when relevant.
Small failures in data completeness can distort coverage estimates, but the broader pattern here is hard to dismiss. All GP IT suppliers provided data for April to June 2022, yet national GP practice participation still varied widely across the quarter, from 93.4% in April and 97.1% in May to 67.9% in June. A lower participation rate in one month can blur local interpretation, but it does not erase the overall downward trajectory seen across the quarter and across recent years.
Pregnancy vaccines work through a straightforward immunological logic: maternal antibody generation followed by placental transfer to the infant before birth. For pertussis, that timing matters because the youngest infants remain most vulnerable before they complete early-life vaccination. Lower uptake during pregnancy narrows that passive protection window and leaves more newborns exposed during a biologically high-risk period.
Infant Case Counts Remain Low, but the Margin for Error Shrinks
The discussion section places the coverage data against recent infant disease activity. Confirmed pertussis cases in infants under 3 months remained extremely low, with 9 confirmed cases between January and March 2022, compared with 0 in the same quarter of 2021 and 16 in the same quarter of 2020. Those numbers are small, but they do not justify complacency. The programme exists precisely because a handful of severe infant cases can carry outsized clinical weight, especially when disease incidence begins to rise again as COVID-19 control measures ease.
The report links that future risk to current uptake. If infant exposure increases, the value of maternal immunisation becomes even more immediate, because the vaccine’s benefit is front-loaded into the neonatal period rather than postponed until the child is old enough to mount a direct vaccine response.
Local Variation Points to Delivery Friction, Not Just Hesitancy
Coverage across regions and STPs varied from strong to poor enough to raise questions about access, workflow, and continuity of antenatal care. Some areas remained high throughout the quarter, including Humber, Coast and Vale at 76.0% for April to June 2022, Dorset at 75.7%, and Joined Up Care Derbyshire at 75.3%. Others lagged well behind, including North London Partners in Health and Care at 29.1%, East London Health and Care Partnership at 35.6%, and Cornwall and The Isles of Scilly Health & Social Care Partnership at 39.5%.
These are not abstract differences. At the bedside, maternal vaccination depends on a clinician raising the issue early, an appointment structure that allows vaccination without delay, and record systems that do not bury the offer until late pregnancy when missed opportunities are harder to recover.
The report’s comparison with earlier years suggests the pandemic may have left a durable mark on routine maternal immunisation delivery. The continuity of antenatal services, patient attendance, and vaccine offer pathways likely shaped the fall seen in 2022, and the London decline suggests the disruption was neither uniform nor random.
Data Quality Limits the Precision, Not the Direction, of the Signal
Coverage estimates are only as accurate as the delivery date and vaccine date recorded in primary care systems. Missing or incomplete entries can understate or misclassify uptake, and the report explicitly notes that completeness of denominator extraction depends on the medical record fields being properly completed. CCGs were omitted from the tables because of changing NHS geographies and their abolition from 1 July 2022, which also complicates long-run comparisons at the local level.
Even with those caveats, the direction of travel is consistent: coverage has fallen, London has fallen the furthest, and national uptake in spring 2022 was the lowest measured since the automated specification began. The operational response now needs to focus on restoring timely antenatal vaccination at the exact point where the infant’s protection begins — before birth, not after exposure.